The rising prevalence of type 2 diabetes and increasing burden of diabetic complications requires new approaches to diabetes therapy. An encouraging new approach for development of future anti-diabetic drugs is based on analogues of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both peptides reduce postprandial glucose by stimulating glucose-dependent insulin release and exert a number of other beneficial actions including trophic effects on the beta-cell. Efforts are currently focused on developing stable analogues of GLP-1 and GIP which are resistant to dipeptidylpeptidase IV mediated degradation and renal filtration. Thus, by increasing the half-life and potency of these incretins, they should become a new class of agents for the treatment of type 2 diabetes.
Unger RH, Eisentraut AMEntero-insular axis. Arch Int Med1969;123: 261-6.
2.
Knowler WC, Pettitt DJ, Saad MF et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nut1991;53: 1543S-51S.
3.
Ohneda M., Inman LR, Unger RHCaloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia1995;38:173-9.
4.
Inzucchi SEOral antihperglycaemic therapy for type 2 diabetes. JAMA2002;287:360-72.
5.
Krentz AJ, Bailey CJOral antidiabetic agents: current role in type 2 diabetes mellitus . Drugs2005;65:385-411.
6.
Gault VA, Flatt PR, O'Harte FPM.Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun2003;308:207-13.
7.
Göke R., Wagner B., Fehmann HC, Goke B.Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med1993;193:97-103.
8.
Green BD, Gault VA, O'Harte FPM, Flatt PRStructurally modified analogues of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) as future antidiabetic agents. Curr Pharm Des2004;10:3651-62.
9.
Farilla L., Bulotta A., Hirshberg B. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology2003;144:5149-58.
10.
Turton MD, O'Shea D., Gunn et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature1996;379:69-72.
11.
Kindmark H. , Pigon J., Efendic S.Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab2001;86:2015-19.
12.
Rudovich NN , Rochlitz HJ, Pfeiffer AFReduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant firstdegree relatives of type 2 diabetic patients. Diabetes2004;53:2359-65.
13.
Groop PH, Groop L., Totterman KJ, Fyhrquist F.Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinol1986;112:361-6.
14.
Meier JJ, Goetze O., Anstipp J. et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab2004 ;286:E621-E625.
15.
Meier JJ, Gallwitz B., Siepmann N. et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia2003;46:798-801.
16.
Barrett AJ, Rawlings NDOligopeptidases, and the emergence of the prolyl oligopeptidase family . Biol Chem1992;373:353-60.
17.
Knudsen LB, Pridal L.Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol1996;318:429-35.
18.
Gault VA, Parker JC, Harriott P., Flatt PR, O'Harte FPM.Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol2002;175:525-33.
19.
Meier JJ, Nauck MA, Kranz D. et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes2004 ;53:654-62.
20.
Gappa H., Baudys M., Koh JJ, Kim SW, Bae YHThe effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets. Tissue Eng2001;7:35-44.
21.
Gutniak MK, Larsson H., Heiber SJ, Juneskans OT, Holst JJ, Ahren B.Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care1996 ;19:843-8.
22.
Burcelin R. , Rolland E., Dolci W., Germain S., Carrel V., Thorens B.Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N Y Acad Sci1999;875:277-85.
23.
O'Harte FPM , Gault VA, Parker JC et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia2002;45:1281-91.
24.
Gault VA, Flatt PR, Bailey CJ et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J2002 ;367:913-20.
25.
Mentlein R.Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides . Regul Pept1999;85:9-24.
26.
Green BD, Gault VA, Flatt PR, Harriott P., Greer B., O'Harte FPM.Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion and in vivo antidiabetic actions following substitution of Ala8/Ala2 for 2-aminobutyric acid. Arch Biochem Biophys2004;428: 136-43.
27.
Holz GG, Chepurny OGGlucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem2003;10:2471-83.
28.
Kapitza C., Trautmann ME, Heise T., Heinemann L., Patterson, B.Daily Administration of LY307161 SR (GLP-1 Analog) Normalizes Blood Glucose in Type 2 Diabetes. Diabetes ADA Meeting San Francisco2002; 341-OR.
Mark M.NN-2211. Novo Nordisk. IDrugs2003 ;6:251-8.
31.
Kreymann B. , Williams G., Ghatei , MA, Bloom, SRGlucagon-like peptide-1 7-36: a physiological incretin in man. Lancet1987;2:1300-04.
32.
Meier JJ, Nauck MA, Siepmann N. et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism2003;52:1579-85.
33.
Nauck MA, El-Ouaghlidi A., Gabrys B. et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept2004;122:209-17.
34.
Kjems LL, Holst JJ, Volund A., Madsbad S.The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes2003;52:380-6.
35.
Meier JJ, Gallwitz B., Kask B. et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes2004;53:S220-S224.
36.
Lindsay JR, Au STB, Kelly CMN, O'Harte FPM, Flatt PRA novel aminoterminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with a prolonged insulinotropic activity in type 2 diabetes mellitus. Diabetes2002;5:1394.
37.
Balkan B., Kwasnik L., Miserendino R., Holst JJ, Li X.Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia1999;42:1324-31.
38.
Ahren B., Holst JJ, Martensson H., Balkan B.Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol2000 ;404:239-45.
39.
Deacon CF, Wamberg S., Bie P., Hughes TE, Holst JJPreservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol2002;172:355-62.
40.
Ahren B., Simonsson E., Larsson H. et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care2002;25:869-75.
41.
Mentlein R.Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin Investig Drugs2005;14:57-64.
42.
Flatt PR, Bailey CJ, Kwasowski P., Swanston-Flatt SK, Marks V.Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice . Diabetes1983;32:433-5.
43.
Bailey CJ, Flatt PR, Kwasowski P., Powell CJ, Marks V.Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets . Acta Endocrinol1986;112:224-9.
44.
Miyawaki K. , Yamada Y., Ban N. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med2002;8:738-42.
